CINECA IRIS Institutional Research Information System

DEL RE, MARZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.240
EU - Europa 3.127
AS - Asia 1.114
AF - Africa 242
OC - Oceania 16
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 11.759
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.128
IT - Italia 1.509
SE - Svezia 538
CN - Cina 433
SG - Singapore 372
BG - Bulgaria 297
DE - Germania 214
GB - Regno Unito 178
CI - Costa d'Avorio 154
VN - Vietnam 132
AT - Austria 114
CA - Canada 110
FI - Finlandia 57
SN - Senegal 55
FR - Francia 47
IN - India 46
TR - Turchia 40
HK - Hong Kong 37
PL - Polonia 30
BE - Belgio 24
NL - Olanda 24
ES - Italia 22
NG - Nigeria 20
UA - Ucraina 17
JP - Giappone 15
RU - Federazione Russa 15
AU - Australia 12
EU - Europa 9
KR - Corea 9
RO - Romania 9
ID - Indonesia 7
CZ - Repubblica Ceca 6
TW - Taiwan 6
ZA - Sudafrica 6
BR - Brasile 5
IE - Irlanda 5
CH - Svizzera 4
NZ - Nuova Zelanda 4
PH - Filippine 4
BF - Burkina Faso 3
BJ - Benin 3
DK - Danimarca 3
HR - Croazia 3
IR - Iran 3
CL - Cile 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
NO - Norvegia 2
PT - Portogallo 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
MX - Messico 1
PE - Perù 1
RS - Serbia 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 11.759
Salva come PNG Salva come JPEG
Città #
Fairfield 897
Woodbridge 872
Houston 603
Ann Arbor 583
Chandler 540
Ashburn 458
Serra 432
Seattle 381
Wilmington 313
Sofia 297
Cambridge 262
New York 246
Boardman 229
Princeton 174
Florence 169
Pisa 162
Abidjan 154
Lawrence 146
Beijing 145
Medford 119
Vienna 113
Singapore 100
Ottawa 99
London 98
Milan 70
San Diego 65
Dearborn 61
Des Moines 60
Nanjing 59
Dakar 55
Dong Ket 51
Frankfurt am Main 47
Turin 41
Bremen 39
Ogden 38
Hong Kong 35
Boulder 33
Los Angeles 33
Rome 31
Izmir 27
Redwood City 27
Warsaw 27
Kunming 23
Washington 21
Hefei 20
Lagos 20
Nanchang 19
Brussels 18
Livorno 18
Changsha 14
Jacksonville 14
Marseille 14
Naples 14
Hebei 13
Norwalk 12
San Francisco 12
Shenyang 12
Chiesina Uzzanese 11
Düsseldorf 11
Lancaster 10
Detroit 9
Genoa 9
Lucca 9
Phoenix 9
Redmond 9
Dallas 8
Guangzhou 8
Jiaxing 8
Kilburn 8
Kocaeli 8
Lappeenranta 8
San Giuliano Terme 8
Shanghai 8
Vicopisano 8
Chengdu 7
Hyderabad 7
Monza 7
Palermo 7
Amsterdam 6
Bologna 6
Cluj-Napoca 6
Indiana 6
Iowa City 6
Nuremberg 6
Pune 6
Torino 6
Toronto 6
Zhengzhou 6
Bloemfontein 5
Cagliari 5
Camaiore 5
Cascina 5
Columbus 5
Duncan 5
Falls Church 5
Grafing 5
Kent 5
Napoli 5
Prato 5
Seacroft 5
Totale 8.932
Salva come PNG Salva come JPEG
Nome #
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer 379
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 239
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 170
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 162
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 159
Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. 146
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 145
null 142
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 140
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 130
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 129
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 128
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 127
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 122
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 119
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 117
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 117
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial 114
null 113
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 112
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 112
Clinical pharmacology of intravitreal anti-VEGF drugs 111
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 111
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? 110
Author's reply. 109
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 108
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 107
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 106
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 106
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 106
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. 105
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 104
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 103
null 101
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 101
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 101
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 101
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 101
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 100
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 100
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 100
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 99
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 97
null 96
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence 96
Pharmacogenetics of anti-estrogen treatment of breast cancer 95
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 95
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors 94
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 94
Genetic variation: effect on prostate cancer 92
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 92
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 91
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 90
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 89
Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position 87
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele 86
Radiomics and liquid biopsy in oncology: the holons of systems medicine 86
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? 85
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 85
Crizotinib resensitization by compound mutation 85
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: A lethal case with a new variant 84
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro 83
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 83
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer 82
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients 82
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 82
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 81
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 80
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment 79
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 79
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 78
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 78
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 77
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 76
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 76
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 75
Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment 75
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA 72
Cross-Linked Hyaluronic Acid as Tear Film Substitute 72
ErbB in NSCLC as a molecular target: Current evidences and future directions 71
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 71
Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. 70
null 70
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 70
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 70
Determinants of bone specific metastasis in prostate cancer 68
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 68
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 68
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 67
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 67
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 65
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 64
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC 61
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs 61
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 61
null 60
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 60
Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC 59
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 59
PROMs in post-mastectomy care: Patient self-reports (BREAST-Q™) as a powerful instrument to personalize medical services 59
Totale 9.810
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.204
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.906 0 0 338 158 208 254 242 196 201 123 145 41
2020/20211.112 64 63 68 111 72 56 114 56 173 78 86 171
2021/20221.488 18 46 22 35 226 267 94 73 100 96 89 422
2022/20232.383 291 318 169 169 193 282 33 153 494 25 226 30
2023/20241.690 99 111 262 78 168 325 95 72 40 85 142 213
2024/2025314 94 203 17 0 0 0 0 0 0 0 0 0
Totale 12.247